BioSpace News Archive

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced a two-year sponsored research agreement with Sunnybrook Research Institute (SRI) to expedite the identification of novel drug candidates that inhibit Bax and Bak with high potency, specificity and appropriate pharmacokinetic properties for the development as therapeutics for neurodegenerative diseases, specifically in amyotrophic lateral sclerosis (ALS).

n-Lorem, a nonprofit foundation, today announced the publication of an invited perspective article authored by n-Lorem founder and CEO, Dr. Stanley Crooke, and titled “Establishing an Environment in Which Rigorous Scientific Inquiry is Practiced”.

Therapeutic Solutions International announced today granting of Emergency IND # 28685 and a “May Proceed Notification” from the Food and Drug Administration (FDA) for the treatment of advanced COVID-19 ARDS outside of the currently ongoing Double Blind Placebo Controlled Phase III clinical trial.

The Lung Cancer Research Foundation (LCRF) is pleased to welcome Matthew Cipriani to its Board of Directors.

Stuart Therapeutics, Inc. ( Stuart ), a clinical stage company headquartered in Stuart, Florida that is developing advanced ophthalmic therapeutics, announced today the results of its Type C Guidance meeting with the U.S. Food and Drug Administration (FDA) regarding the continued development plan for ST-100.

Verana Health®—a digital health data company elevating quality in real-world data—delivered two podium presentations at the American Society of Retina Specialists (ASRS) 2022 Annual Meeting in New York City on July 15.

Genmab A/S announced that AbbVie will submit a conditional marketing authorization application with the European Medicines Agency for subcutaneous epcoritamab, an investigational bispecific antibody, for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma, in the second half of 2022.

Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, announces today that it has made three new appointments to its scientific and operations teams, to support growth and accelerate its R&D.

GeneIQ, a molecular diagnostics company based in Dallas, Texas, welcomes Sami Shihabi as their new Chief Commercial Officer.

BELLUS Health Inc. announced that it has completed its previously-announced underwritten public offering in Canada and the United States of 16,540,541 common shares at a price to the public of US$9.25 per common share.